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The discoidin domain receptors, (DDR)1 and DDR2, have been linked to numerous human cancers. We sought to determine
expression levels of DDRs in human lung cancer, investigate prognostic determinates, and determine the prevalence of recently
reported mutations in these receptor tyrosine kinases. Tumour samples from 146 non-small cell lung carcinoma (NSCLC) patients
were analysed for relative expression of DDR1 and DDR2 using quantitative real-time PCR (qRT-PCR). An additional 23 matched
tumour and normal tissues were tested for differential expression of DDR1 and DDR2, and previously reported somatic mutations.
Discoidin domain receptor 1 was found to be significantly upregulated by 2.15-fold (P¼0.0005) and DDR2 significantly
downregulated to an equivalent extent (P¼0.0001) in tumour vs normal lung tissue. Discoidin domain receptor 2 expression was
not predictive for patient survival; however, DDR1 expression was significantly associated with overall (hazard ratio (HR) 0.43, 95%
CI¼0.22–0.83, P¼0.014) and disease-free survival (HR¼0.56, 95% CI¼0.33–0.94, P¼0.029). Multivariate analysis revealed
DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
However, contrary to previous work, we did not observe DDR mutations. We conclude that whereas altered expression of DDRs
may contribute to malignant progression of NSCLC, it is unlikely that this results from mutations in the DDR1 and DDR2 genes that
we investigated.
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Lung cancer is the leading cause of cancer-associated deaths
worldwide and has one of the poorest prognoses among all cancer
types. Non-small cell lung carcinoma (NSCLC) comprises approxi-
mately 80% of lung cancer, and its overall 5-year survival rate is
15%. Early stage tumours are treated primarily by complete
surgical resection, yet 30–55% of patients will develop recurrence
and die of the disease. Despite significant advances achieved in the
chemotherapy and radiation therapy for advanced disease patients,
most patients will eventually develop resistance. Thus, there is a
need for novel and effective targeted therapies, the development of
which requires our greater understanding of the genetic abnorm-
alities in lung cancers.
As the complexity and unique nature of individual human
cancers become apparent, the analysis of individual patients’
genetic makeup has become important in guiding the development
of novel treatments. A striking example of this has recently
emerged in therapies using the epidermal growth factor receptor
(EGFR) small molecule inhibitors (Shepherd et al, 2005; Tsao et al,
2005; Blackhall et al, 2006). Somatic mutations in the tyrosine
kinase domain and copy number changes of the EGFR gene play
critical roles in determining the sensitivity and clinical benefit of
NSCLC patients treated by EGFR inhibitor drugs.
The discoidin domain receptors (DDRs) are receptor tyrosine
kinases (RTKs) belonging to the same enzyme family as EGFR. The
DDR1 gene is divided into 19 exons and has a coding sequence of
2742bp. Discoidin domain receptor 2 is also divided into 19 exons
and encodes a 2568bp mRNA. Discoidin domain receptor 1 and
DDR2 share similar structures, consisting of a characteristic
discoidin homology domain, stalk region, transmembrane region,
juxtamembrane region, and kinase domain. Compared to other
RTKs, DDRs are unique because they have native collagens as their
ligands. Discoidin domain receptors have been shown to exhibit
altered expression patterns in multiple human cancers, including
breast, oesophageal, ovarian, brain and lung tumours (Vogel et al,
2006). Of note, DDR1 appears to be preferentially expressed in
tumour cells, whereas DDR2 is expressed in tumour stroma (Alves
et al, 1995). The mechanism by which these receptors may
contribute to oncogenesis is as yet unknown; however, given their
important role in transmitting signals from the extracellular matrix
(ECM), it is possible that they act as regulators of cell proliferation,
adhesion, migration, and subsequent tumour metastasis. Similar to
EGFR it is conceivable that altered expression and/or mutation of
DDRs trigger abnormal activity, ultimately leading to enhanced
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sproliferation and oncogenic transformation. The mutations in
EGFR are all found within the catalytic kinase domain, and mostly
consist of single-point mutations or small deletions (Sakurada
et al, 2006; Shigematsu and Gazdar, 2006). In a related study,
Davies et al (2005) screened for mutations in lung cancer by
comprehensively sequencing all 518 kinases in the human genome.
Among mutations in several other RTKs, the authors also
described novel somatic mutations in DDRs, specifically the
mutations A496S and R824W for DDR1 and the mutation R105S
for DDR2.
Here, we sought to extensively explore the association of DDRs
with human lung cancer by determining their expression levels
and the prevalence of the newly reported mutations in a larger
cohort of NSCLC primary tumours and tumour cell lines. We
demonstrated a significant upregulation of DDR1 and a down-
regulation of DDR2 in lung tumour tissue compared with matched
normal tissues from the same patients; importantly we demon-
strated that DDR1 expression was a good prognostic marker for
early-stage NSCLC patients. However, we did not identify any of
the three previously identified mutations in our cohort of lung
cancers or in any of the cell lines tested.
MATERIALS AND METHODS
Patients
A total of 146 primary lung tumours and an independent set of 23
matched tumour and normal lung tissue samples were harvested
from NSCLC patients treated by surgical resection without
adjuvant chemotherapy at the University Health Network and
Mount Sinai Hospital, Toronto, Canada (Table 1A). Tissues were
harvested within 30min after complete resection, and the quality
and pathology of tumour tissue was confirmed by the study
pathologist (M-ST). Samples with a tumour-cell content of at least
50% were used in the study. The University Health Network
Research Ethics Board has approved the use of these samples and
their associated clinical information in this study.
Cell lines and xenograft models
Human cell lines (ATCC) were cultured and grown in media
according to the manufacturer’s recommended conditions
(Table 2). A lung xenograft model had been generated previously
and no additional animal experiments were necessary for the
current work (Liu and Tsao, 1993). Briefly, 2 10
6 cells in 70ml
medium (RPMI-1640, 10% fetal bovine serum) containing 10%
Matrigel (BD Bioscience, San Jose, CA, USA) were subcutaneously
injected into the ventral abdomen of 5-week-old male severe
combined immunodeficiency mice (Table 2). Formation of
tumours was observed by palpation, and growth measured twice
a week until the tumour reached a volume of 1cm
3. After mice
were killed, tumour tissue was harvested and snap-frozen in liquid
nitrogen. All animals received humane care in compliance with the
Guide to the Care and Use of Experimental Animals issued by the
Canadian Council of Animal Care. All animal procedures were
performed in accordance with a protocol approved by the animal
care committee of the University of Toronto.
RNA extraction
Ribonucleic acid was extracted from patient samples and cell lines
using the method of Chomczynski and Sacchi (1987); extracts were
purified using the RNeasy kit (Qiagen, Hilden, Netherlands),
DNase treated (Ambion, Austin, TX, USA), and quantified via
spectrophotometry. Ribonucleic acid quality was assessed by
agarose gel electrophoresis.
Table 1A Comparative clinical and pathological features of the full cohort of NSCLC patients. Patients were dichotomised using the median level of
DDR1 expression, whereas patients with undetectable DDR2 were considered low expressors
All patients (146) Elevated DDR1 expression (73) Reduced or absent DDR2 expression (104)
Histology
Adenocarcinoma 92 (63%) 39 (53%) 63 (61%)
Squamous cell carcinoma 54 (37%) 34 (47%) 41 (39%)
Pathological stage
Stage I 95 (65%) 51 (70%) 62 (60%)
Stage II 34 (23%) 15 (21%) 30 (29%)
Stage III 17 (12%) 7 (9%) 12 (11%)
T stage
T1 45 (31%) 28 (38%) 30 (29%)
T2 92 (63%) 43 (59%) 68 (65%)
T3 9 (6%) 2 (3%) 6 (6%)
N stage
N0 94 (64%) 51 (70%) 65 (63%)
N1 38 (26%) 16 (22%) 30 (29%)
N2 14 (10%) 6 (8%) 9 (8%)
Differentiation
WD 32 (23%) 18 (25%) 21 (20%)
MD 39 (27%) 21 (29%) 29 (28%)
PD 37 (25%) 16 (22%) 30 (29%)
U 37 (25%) 18 (24%) 24 (23%)
Sex
Male 63 (43%) 32 (44%) 47 (45%)
Female 83 (57%) 41 (56%) 57 (55%)
Median Survival time (years) 3.89 4.98 4.29
MD¼moderately differentiated; PD¼poorly differentiated; WD¼well differentiated; U¼unknown.
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tumour samples
Quantitative real-time PCR (qRT-PCR) was conducted using the
SYBR Green assay in the ABI PRISM 7900-HT (Applied
Biosystems, Foster city, CA, USA). Each 10ml qRT-PCR aliquet
contained a 2ng equivalent of cDNA in a 384-well plate. The
reactions were activated at 951C for 3min followed by 40 cycles of
951C (15s), 651C (15s) and 721C (20s). The amount of transcript
per ng cDNA was calculated using standard curves generated using
a pool of genomic DNA from 10 normal lung tissue samples as
described (Yun et al, 2006). Primer sequences were designed with
Primer Express v 2.0 (Applied Biosystems). Primer sequences for
DDR1 were forward primer ATGGAGCAACCACAGCTTCTC,
reverse primer CTCAGCCGGTCAAACTCAAACT, and for DDR2,
forward primer GGAGGTCATGGCATCGAGTT, reverse primer
GAGTGCCATCCCGACTGTAATT. Technical replicates displayed
high correlation (Ravg¼0.9570.03) and were collapsed by
averaging. Expression values were then log2-transformed. Stan-
dardisation and normalisation were conducted using the geometric
mean of the expression levels of four normaliser genes (ACTB,
forward primer TCCTAAAAGCCACCCCACTTCT, reverse primer
GGGAGAGGACTGGGCCATT, TBP, forward primer GGGCATT
ATTTGTGCACTGAGA, reverse primer TAGCAGCACGGTATGA
GCAACT, BAT1, forward primer CGGTATCAGCAGTTTAAAG
ATTTTCA, reverse primer TGCCTCGGCCAAATAGGTT, and
B2M, forward primer GAGTGCTGTCTCCATGTTTGATGT, reverse
primer AAGTTGCCAGCCCTCCTAGAG). An indepth description
of this method was published recently (Barsyte-Lovejoy et al,
2006).
PCR and sequencing analysis
Total RNA was transcribed into cDNA using Superscript II Reverse
Transcriptase and oligo-dT (Invitrogen, Carlsbad, CA, USA).
Primers were designed to amplify the regions containing
previously identified DDR mutations in the juxtamembrane
(forward primer GAGCTGACGGTTCACCTCTC, reverse primer
AATGTCAGCCTCGGCATAAT), and kinase domains (forward
primer GGTGCTGATGCTCTGTAGGG, reverse primer CGTGT
TGAGTGCATCCTCTG) of DDR1 and the discoidin domain of
DDR2 (forward primer GACTTGCACACCCTCCATTT, reverse
primer GAGTGGTCGGTGACTGGAAT). The housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase (forward primer
CAATGACCCCTTCATTGACC, reverse primer TGCTGTAGCCA
AATTCGTTG), was used as a control. cDNA was subjected to PCR
amplification consisting of an initial 2min denaturation at 941C,
followed by 35 cycles of amplification (941C, 30s; 571C, 30s; 721C,
45s), and a final extension at 721C for 3min. Polymerase chain
reaction products were subjected to agarose gel electrophoresis
with appropriate size markers, and samples producing bands of
the correct size were purified using the MiniElute PCR Purification
kit (Qiagen). Purified samples were sequenced at The Centre for
Applied Genomics (TCAG) facility in Toronto, Canada, using an
ABI3730XL DNA sequencer. Samples were sequenced in both
directions using the same primers as for amplification, and
sequences aligned and analysed using ChromasPro software
(Technelysium, Tewantin, Australia). Samples that gave ambig-
uous sequences were repeated up to three times. Two samples
were excluded from the study as clean sequences could not be
generated.
Genomic sequencing
Additionally, DNA was extracted from all 12 lung cancer cell lines
using standard techniques. Polymerase chain reaction was
performed using exon-specific primers spanning putative muta-
tion sites in DDR1 and DDR2, and PCR product sequenced as
outlined above.
Statistical analysis
Matched t-tests were used to determine differential expression of
DDR1 and DDR2. The Spearman’s correlation, Kruskal–Wallis,
Table 1B Cohort of matched tumour and normal lung tissues with relative DDR1 and DDR2 expression levels. Expression values were calculated relative
to that of four normalizer genes
Tumour Histology Stage T N Differentiation Sex Relative DDR1 expression Relative DDR2 expression
1 SQ 1B T2 N0 PD F 7.25 0.00443
2 SQ 1A T1 N0 PD F 5.21 0.0364
3 AD 3A T2 N2 PD M 2.16 0.0846
4 AD 2B T2 N1 PD F 5.06 0.0626
5 AD 3A T1 N2 WD F 22.1 0.0271
6 AD 1A T1 N0 MD M 26.5 0.0493
7 AD 1B T2 N0 WD M 12.4 0.00648
8 SQ 1B T2 N0 MD F 14.2 0.0684
9 AD 3A T2 N2 PD F 7.21 0.0563
10 AD 1B T2 N0 PD M 3.00 0.0163
11 SQ 1A T1 N0 PD M 5.74 0.0264
12 AD 1A T1 N0 PD M 0.91 ND
13 SQ 1A T1 N0 MD M 22.38 0.0193
14 AD 1B T2 N0 PD F 11.66 0.00947
15 SQ 1B T2 N0 MD F 6.67 0.0475
16 SQ 1B T2 N0 MD F 11.94 0.0575
17 AD 1B T2 N0 PD M 6.46 0.0270
18 LCUC 1B T2 N0 PD U 3.65 0.0363
19 SQ 1A T1 N0 MD M 19.74 0.0213
20 SQ 2B T2 N1 MD M 19.66 0.0813
21 LCUC 1B T2 N0 PD F 14.82 0.00651
22 AD 1B T2 N0 PD F 13.86 0.0215
23 AD 2B T3 N0 PD F 4.92 0.0937
AD¼adenocarcinoma; DDR1¼discoidin domain receptor 1; DDR2¼discoidin domain receptor 2; LCUC¼large cell undifferentiated carcinoma; MD¼moderately
differentiated; ND¼expression level below detection limit; PD¼poorly differentiated; SQ¼squamous cell carcinoma; U¼data not available; U¼status unknown; WD¼well
differentiated.
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between molecular indices and the pathological or clinical factors.
The end points for analyses were overall survival (from date of
surgery to date of death) and disease-free survival (from date of
surgery to date of disease recurrence). The Cox proportional
hazards model was used to test the association of survival and
DDR1 expression, where DDR1 expression was treated as a
continuous variable. For Kaplan–Meier and multivariate analysis,
subjects were dichotomised according to the median expression
levels of DDR1 (median¼32.6); low DDR1 expressors are defined
as patients with expression levels below the median, whereas high
DDR1 expressors are those with expression values above the
median. Discoidin domain receptor 2 cases were dichotomised
based on expressors vs nonexpressors. The Cox proportional
hazards model was employed for the multivariate analysis. All
statistical analysis was conducted using SAS software (v9.1).
RESULTS
Quantitative real-time PCR analysis of DDR1 and DDR2 expres-
sion performed on the 146 NSCLC tumour samples (full data set
available as Supplementary Table S1) showed neither DDR1 nor
DDR2 were associated with factors such as tumour stage (P¼0.38
and P¼0.51, respectively), differentiation (P¼0.93 and P¼0.60,
respectively), and age (Spearman’s correlation P¼0.82 and
P¼0.48, respectively). Normalised DDR1 expression ranged from
0 to 1184 transcript copies per 2ng of cDNA, whereas DDR2
expression ranged from 0 to 186 copies. The expression of DDR1
was significantly higher in squamous cell carcinoma than in
adenocarcinoma (P¼0.007; median expression 40.6 vs 23.1,
respectively). In contrast to DDR2 whose expression level was
not prognostic (Supplementary Table S2), high expression of
DDR1 was associated with significantly favourable overall survival
in this cohort of patients (HR¼0.43, 95% CI¼0.22–0.83,
P¼0.014) (Figure 1A). Discoidin domain receptor 1 expression
was also significantly associated with greater disease-free survival
(HR¼0.56, 95% CI¼0.33–0.94, P¼0.029) (Figure 1B). In multi-
variate analysis, DDR1 expression remained significant in
predicting overall survival (HR¼0.5, 95% CI¼0.26–0.97,
P¼0.04), but not disease-free survival, after adjustments for stage,
differentiation, histology, and age.
Next, we analysed a cohort of 23 samples from lung cancer
patients, which included matched normal tissue for each tumour
sample. Discoidin domain receptor 1 was shown to be upregulated
by 2.15-fold (P¼0.0005), and DDR2 downregulated by an
equivalent amount (1.94-fold, P¼0.0001) in tumour tissue
compared with matched normal samples (Table 1B, Figure 2).
We then analysed the genetic sequences of DDR1 and DDR2 in this
cohort. To our surprise, we failed to detect any of the previously
identified mutations in DDR1 and DDR2, nor any new mutations
(Davies et al, 2005). We then subjected 12 lung cell lines, six lung
xenografts, and 15 other cell lines to sequence analysis. The 12 lung
cell lines were also subjected to genomic sequencing. Again, none
of the previously reported mutations was found. This group
included the lung cell line NCI-H1770 that had previously been
reported to harbour the R824W mutation in the DDR1 kinase
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Figure 1 Kaplan–Meier analysis of (A) overall survival and (B) disease-
free survival, according to DDR1 expression levels. Patients were
dichotomised based on the median level of DDR1 expression.
Table 2 List of cell lines and xenografts used for sequence analysis
Name Pathology
Lung cell lines
A549 AD
H125 ADSQ
H1264 SQ
H157 SQ
H226 SQ
H358 BAC
H460 LCC
H520 SQ
H661 LCC
H1184 SQ
NCI-H1770 NE
RVH6849 AD
Lung xenografts
MGH4 LCC
MGH7 SQ
MGH8 AD
MGH13 AD
MGH24 AD
MGH30 ADSQ
Other cell lines
NTERA2 Testicular cancer
HTB126 Breast
HepG2 Hepatoblastoma
HT1080 Fibrosarcoma
SW872 Liposarcoma
T47D Breast carcinoma
MCF7 Breast carcinoma
MCF12A Breast
Colo205 Colon carcinoma
MOLT-4 Leukaemia
SKOV3 Ovarian adenocarcinoma
SKMEL28 Melanoma
MCF10A Breast
HEK293 Kidney
MDAMB231 Breast carcinoma
AD¼adenocarcinoma; ADSQ¼adenosquamous carcinoma; BAC¼bronchoalveo-
lar carcinoma; LCC¼large cell carcinoma; SQ¼squamous cell carcinoma;
NE¼neuroendocrine tumour.
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mutation in either DNA or RNA sequences from this cell line.
Sequences were generated for almost 20% of the coding sequence
of DDR1, and 10% of DDR2.
Previously identified polymorphisms located in these regions
were successfully identified, confirming the robust nature and
specificity of the sequencing method employed. One previously
identified polymorphism in DDR1, located at amino acid 495, was
identified in 46% of the clinical samples screened. This poly-
morphism is directly adjacent to the DDR1 A496S mutation
identified by Davies et al (2005) that was not identified in any
sample of our cohort (Figure 3B). This polymorphism is a
synonymous change, and is therefore unlikely to be of functional
importance; however, it is of interest to note that whereas six of 23
samples harboured this change in both their normal and tumour
tissues suggestive of a germline polymorphism, another nine
samples recorded the change only in their tumour tissue,
indicating an acquired or somatic aetiology.
DISCUSSION
We have demonstrated for the first time that the expression of
DDRs is significantly deregulated in NSCLC. Furthermore we have
shown that DDR1 is an independent favourable prognostic marker
for early-stage NSCLC patients, and that mutations in DDR1 and
DDR2 appear less frequently than previously reported. The
collagen-binding RTKs, DDR1 and DDR2, have previously been
linked to various human diseases including fibrosis (Alves et al,
1995; Mao et al, 2002; Lee et al, 2004; Avivi-Green et al, 2006),
atherosclerosis (Hou et al, 2001; Hou et al, 2002; Ferri et al, 2004),
and cancer (Johnson et al, 1993; Alves et al, 1995; Barker et al,
1995; Nemoto et al, 1997; Weiner et al, 2000; Dejmek et al, 2003;
Ongusaha et al, 2003; Heinzelmann-Schwarz et al, 2004; Ram et al,
2006; Vogel et al, 2006). The mechanism by which DDRs may
contribute to oncogenesis is as yet unknown.
Although DDR1 has been previously discussed in the context
of idiopathic pulmonary fibrosis and inflammation of the lung
(Avivi-Green et al, 2006; Matsuyama et al, 2006a,b), a direct link
with lung tumorigenesis has not yet been established. In addition,
DDR2 has not yet been investigated in the context of lung cancer.
This therefore represents the first study to extensively explore and
quantify the expression levels of these unique RTKs in a large
clinical cohort of lung cancer patients. Discoidin domain receptor
1 was shown to be upregulated in tumour vs normal tissue,
whereas DDR2 was downregulated. Intriguingly, our data suggest
that higher DDR1 expression can also be a strong independent
prognostic indicator for early-stage NSCLC patients. Although
DDR2 also appeared to be protective in our cohort, there were
ultimately too few cases with quality expression data to make a
firm conclusion. These results detailing differences in expression
at the mRNA level are also of interest in relation to previous
reports that DDR1 exhibits preferential protein expression in
tumour epithelial cells, whereas DDR2 is more commonly
expressed in the surrounding stroma (Alves et al, 1995). At this
stage, it remains unknown as to the mechanisms by which DDRs
may contribute to oncogenesis.
We were interested to note the recent study reporting for the
first time somatic mutations in DDR1 and DDR2 (Davies et al,
2005). The authors report mutations in two patient samples (one
squamous cell carcinoma and one large cell carcinoma), and one
lung cancer cell line (NCI-H1770). However, we could not confirm
the existence of the DDR1 mutation in the NCI-H1770 neuroendo-
crine cell line, which we obtained from ATCC and passaged for
three times only. Despite repeated amplification, sequencing and
analysis of both forward and reverse sequences, the wild-type
DDR1 sequence was observed consistently. Davies et al (2005)
comment on the unusually large number of mutations in the NCI-
H1770 cell line cultured in their laboratory and suggest that this
may be indicative of a defect in DNA repair that mimics UV
exposure. The apparent discrepancy between the two sets of results
may also be owing to differences in clonal strains of the NCI-
H1770 cell lines, and passage number at the time of sequence
analysis. Furthermore, we amplified and sequenced 33 cell lines
(including 12 lung cell lines and six xenografts) and 46 clinical
samples (RNA extracted from 23 matched lung tumour and normal
tissue) from patients treated at our institution and did not identify
any of the three mutations reported by Davies et al (2005).
Several explanations exist for this disparity. Lung cancer
encompasses a broad range of clinical subtypes, and the makeup
of the two cohorts differed. We cannot conclude that differences
were owing to our methodology as our PCR and sequencing
Sample  DDR1 
mutations/polymorphisms
DDR2 mutations 
Mutation location  A496S  S495S   R824W  R105S 
Clinical lung tumour 
tissue 
0/23  15/23  0/23  0/23 
Clinical lung normal tissue 0/23  6/23 0/23  0/23 
Lung cancer cell lines  0/12  1/12  0/12  0/12 
Lung cancer xenografts  0/6  0/6  0/6  0/6 
Other cell lines  0/15  0/15 0/15  0/15 
9 7 / 0 9 7 / 0 9 7 / 2 2 9 7 / 0 l a t o T
ccgccccactccgctccctgtgtcccc
P  P  H  S  A  P  C  V  P
g>t Alanine to serine  c>t Serine to serine 
A
B
Figure 3 Results of sequence analyses. (A) Location of S495S
synonymous change adjacent to A496S somatic mutation identified
previously. (B) Overall prevalence of DDR1 mutations in clinical lung
cohort and cell lines. Six patients had the S485S polymorphism in both
their normal and tumour tissue.
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Figure 2 Accumulated plot of DDR qRT-PCR data demonstrating
relative expression of DDR1 and DDR2 in normal and cancerous tissues
from lung cancer patients. Discoidin domain receptor 1 was found to be
significantly upregulated by 2.15-fold (P¼0.0005) and DDR2 significantly
downregulated by an equivalent amount (P¼0.0001) in tumour tissue
compared with normal tissue from lung cancer patients. Expression values
were calculated relative to that of four normaliser genes.
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we managed to detect both germline and acquired polymorphisms
in our samples, thereby verifying our ability to detect mutations if
they existed in our population. One synonymous nucleotide
change in DDR1 was present in almost half of our clinical cohort.
This polymorphism is located at amino acid 495, directly adjacent
to amino acid 496, previously identified as the site of a somatic
mutation in DDR1. The nucleotide change is a cytosine to a
thymine change located at the third nucleotide of the codon,
resulting in no alteration in the amino acid serine. The previously
identified A496S mutation results from a change from a guanine
to a thymine (Davies et al, 2005). The two altered thymine
nucleotides are sequential, suggesting that this region of the DDR1
genome may be a hotspot for genetic variation (Glover et al, 2005).
We must therefore conclude that if these recently reported DDR1
and DDR2 mutations are valid, then their prevalence must be
much lower in the general lung cancer population than expected.
This does not however rule out the possibility that they are
important mutations contributing clinically to a subset of lung
cancers in certain populations. This is analogous to the emerging
understanding of the role of EGFR mutations in various
populations. As we understand more about the role of RTKs in
cancer, it has become important to investigate the presence and
prevalence of mutations in these genes, in varied populations. We
suggest further research into the presence of mutations in diverse
cohorts from varied populations.
This is the first study to show a strong association of the
collagen binding RTK, DDR1 with human lung cancer. We have
conclusively shown that DDR1 is significantly more (2.15-fold)
expressed in tumour as opposed to normal tissues from lung
cancer patients, and have demonstrated that it can also be a strong
prognostic indicator. Further research is required into the
mechanisms by which both DDR1 and DDR2 function in lung
carcinogenesis.
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